Pharmaceutical Commerce
CONTINUE TO SITE

OR WAIT null SECS

Pharmaceutical Commerce - Biopharma Business News, Market Insights
Spotlight
Digital EditionsSecurityAsembia AXS25 Summit
Topics
View MoreCold ChainData and TechnologyLegal and RegulatoryManufacturing and PackagingOpinionSupply Chain Logistics
News
NewsPharma Pulse
AcademyPublicationsPartner PerspectivesWebcastsResources
Conferences
Conference CoverageConference Listing
Events
Videos
VideosPeer Exchange
Podcasts
Editorial PodcastsSponsored Podcasts
Subscribe

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
  • MJHLS Brand Logo

© 2025 MJH Life Sciences and Pharmaceutical Commerce - Biopharma Business News, Market Insights. All rights reserved.

Spotlight
  • Digital Editions
  • Security
  • Asembia AXS25 Summit
TopicsSee All >
  • Cold Chain
  • Data and Technology
  • Legal and Regulatory
  • Manufacturing and Packaging
  • Opinion
  • Supply Chain Logistics
  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
  • MJHLS Brand Logo

© 2025 MJH Life Sciences™ and Pharmaceutical Commerce - Biopharma Business News, Market Insights. All rights reserved.

Featured Content

Click here to read the articles and view the interactive digital edition

Pharmaceutical Commerce - August 2025

Click here to read the articles and view the interactive digital edition

wholesalers

Pharma Wholesalers: Looking for Growth

Despite the ongoing turmoil over tariffs, medicine costs, and FDA policy, US wholesalers are performing well.

GTN bubble

Popping the Gross-to-Net Bubble, Part V: Innovative Pricing Models

From rethinking launch price logic to implementing rebate-aware modeling and patient-first access programs, this installment explores how disciplined governance and forward-thinking models can safeguard profitability in a volatile market.

340B litigation

340B Litigation and the Path Toward Transparent Drug Discount Programs

As pharma drug pricing debates heat up, the 340B program faces mounting challenges from outdated regulations, duplicate discounts, and limited transparency.